Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab and Anlotinib in ES-SCLC
NCT05896059Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- May 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, anlotinib in small cell lung cancer (SCLC), sponsored by Zhejiang Cancer Hospital. Started May 2023; status: recruiting.
02
Drugs
tislelizumabanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05896059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896059.